PF-06865571 + metformin

**PF-06865571 + metformin** is a combination therapy involving PF-06865571, a diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor, and metformin, a biguanide antihyperglycemic agent. PF-06865571 acts by inhibiting DGAT2, an enzyme crucial for triglyceride synthesis, thereby reducing hepatic steatosis and inflammation, while metformin mainly decreases hepatic glucose production and improves insulin sensitivity. This combination is being developed primarily for the treatment of nonalcoholic steatohepatitis (NASH), as well as for investigation of their pharmacokinetic interaction in healthy adults. Pfizer is the developer of PF-06865571.